Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration

NCT05787028 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
DRUG: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg

Sponsor

South China Center For Innovative Pharmaceuticals

Collaborators

[object Object]